Efficacy for lung metastasis induced by the allogeneic bEnd3 vaccine in mice

References

• Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer[J]. J Clin Oncol. 2003;21(1):60–5. doi:10.1200/JCO.2003.10.066.
   PubMed Web of Science ®Google Scholar
• Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301[J]. J Clin Oncol. 2006;24(21):3354–60. doi:10.1200/JCO.2005.05.1573.
   PubMed Web of Science ®Google Scholar
• Zhou ZT, Xu XH, Wei Q, Lu MQ, Wang J, Wen CH. Erlotinib in advanced non-small-cell lung cancer after gefitinib failure[J]. Cancer Chemoth Pharm. 2009;64(6):1123–7. doi:10.1007/s00280-009-0973-1.
   PubMed Web of Science ®Google Scholar
• Lee DH, Kim SW, Suh C, Yoon DH, Yi EJ, Lee JS. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment[J]. Ann Oncol. 2008;19(12):2039–42. doi:10.1093/annonc/mdn423.
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma[J]. J Clin Oncol. 2008;26(32):5204–12. doi:10.1200/JCO.2007.15.6331.
   PubMed Web of Science ®Google Scholar
• Chen R, Wang S, Yao Y, Zhou Y, Zhang C, Fang J, Zhang D, Zhang L, Pan J. Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide[J]. Oncol Rep. 2015;33(5):2269–76. doi:10.3892/or.2015.3820.
   PubMed Web of Science ®Google Scholar
• Perez Sanchez L, Morera Diaz Y, Bequet-Romero M, Ramses Hernández G, Rodríguez Y, Castro Velazco J, Puente Pérez P, Ayala Avila M, Gavilondo JV. Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate[J]. Hum Vaccin Immunother. 2015;11(8):2030–7. doi:10.1080/21645515.2015.
   PubMed Web of Science ®Google Scholar
• Yu-Quan W, Wang Q, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine[J]. Nat Med. 2000;6(10):1160–6. doi:10.1038/80506.
   PubMed Web of Science ®Google Scholar
• Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, Yazawa K, Asakage M, Tsuchiya T, Sakurai D, et al. A novel method for isolation of endothelial cells and macrophages from murine tumors based on Ac-LDL uptake and CD16 expression[J]. J Immunol Methods. 2004;295(1):183–93. doi:10.1016/j.jim.2004.10.005.
   PubMed Web of Science ®Google Scholar
• Chen XY, Zhang W, Zhang W, Wu S, Bi F, Su YJ, Tan XY, Liu JN, Zhang J. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity[J]. Clin Cancer Res. 2006;12(19):5834–40. doi:10.1158/1078-0432.CCR-06-1105.
   PubMed Web of Science ®Google Scholar
• Gong FL. Medical immunology[M]. Beijing, China: Science Press; 2012.
   Google Scholar
• Hu B, Wei Y, Tian L, Zhao X, Lu Y, Wu Y, Yao B, Liu J, Niu T, Wen Y, et al. Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor[J]. J Immunother. 2005;28(3):236–44. doi:10.1097/01.cji.0000161394.11831.3f.
   PubMed Web of Science ®Google Scholar
• Ankathatti MM, Deng Y, Mulligan SJ, Xiang J. Th17 and Th17-stimulated CD8⁺ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity[J]. Cancer Immunol Immunother. 2011;60(10):1473. doi:10.1007/s00262-011-1054-y.
   PubMed Web of Science ®Google Scholar
• Wullenweber-Schmidt M, Meyer B, Kraft V, Kaspareit J. An enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to Pasteurella pneumotropica in murine colonies[J]. Lab Anim Sci. 1988;38(1):37–41.
   PubMedGoogle Scholar
• Zhao F, He S, He L, Lin M, Wang S, Chen Z. The expression of human IL-37 in E. coli and preparation and characterization of mouse anti-IL-37 antibody[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi Chin J Cell Mol Immunol. 2014;30(5):513–6. doi:10.13423/j.cnki.cjcmi.007066.
   PubMedGoogle Scholar
• Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M, Ba Y, Becker JC, Reisfeld RA. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication[J]. Cancer Res. 2005;65(2):553–61.
   PubMed Web of Science ®Google Scholar
• Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD, Ponnazhagan S. Cancer gene therapy using mesenchymal stem cells expressing interferon-in a mouse prostate cancer lung metastasis model[J]. Gene Therapy. 2008;15(21):1446. doi:10.1038/gt.2008.101.
   PubMed Web of Science ®Google Scholar
• Chopra A. Microbubbles coated with biotinylated rabbit anti-mouse endoglin monoclonal antibody[J]. Molecular imaging and contrast agent database (MICAD). Bethesda (MD): National Center for Biotechnology Information (US); 2004.
   Google Scholar
• Tung YT, Chen HL, Yen CC, Lee PY, Tsai HC, Lin MF, Chen CM. Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor[J]. J Dairy Sci. 2013;96(4):2095–106. doi:10.3168/jds.2012-6153.
   PubMed Web of Science ®Google Scholar
• Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis[J]. Cancer Cell. 2002;2(4):289–300. doi:10.1016/S1535-6108(02)00153-8.
   PubMed Web of Science ®Google Scholar
• T Paauwe M, Heijkants RC, Oudt CH, Hardwick JC, Sier CF, Hawinkels LJ. Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer[J]. Oncogene. 2016;35(31):4069–79. doi:10.1038/onc.2015.509.
   PubMed Web of Science ®Google Scholar
• Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, et al. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer[J]. Clinical Cancer Res. 2013;19(1):170–82. doi:10.1158/1078-0432.CCR-12-1045.
   PubMed Web of Science ®Google Scholar
• Huang Y, Carbone DP. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer[J]. Biochim Biophys Acta. 2015;1855(2):193–201. doi:10.1016/j.bbcan.2015.01.003.
   PubMed Web of Science ®Google Scholar
• Bie N, Zhao X, Li Z, Qi G. Constructing Tumor Vaccines Targeting for Vascular Endothelial Growth Factor (VEGF) by DNA Shuffling[J]. J Immunother. 2016;39(7):260–8. doi:10.1097/CJI.0000000000000129.
   PubMed Web of Science ®Google Scholar
• Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer[J]. Cancer Res. 2013;73(2):539–49. doi:10.1158/0008-5472.CAN-12-2325.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet. 2014;383(9911):31–9. doi:10.1016/S0140-6736(13)61719-5.
   PubMed Web of Science ®Google Scholar
• Falcon BL, Chintharlapalli S, Uhlik MT, Pytowski B. Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents[J]. Pharmacol Ther. 2016;164:204–25. doi:10.1016/j.pharmthera.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Saad RS, Jasnosz KM, Tung MY, Silverman JF. Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol. 2003;22(3):248–53. doi:10.1097/01.PGP.0000070852.25718.37.
   PubMed Web of Science ®Google Scholar
• Saad RS, El-Gohary Y, Memari E, Liu YL, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma[J]. Hum Pathol. 2005;36(9):955–61. doi:10.1016/j.humpath.2005.06.019.
   PubMed Web of Science ®Google Scholar
• Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going?[J]. Br J Cancer. 2004;90(1):1–7. doi:10.1038/sj.bjc.6601401.
   PubMed Web of Science ®Google Scholar
• Yue F, Zhang GP, Jin HM, Shi LG, Yin LH. Cytological characteristics and gene micro-array analysis of a mouse brain microvascular endothelial cell strain:bEnd.3[J]. Chin J Pathophysiol. 2004;20(8):1340–4. doi:10.3321/j.issn:1000-4718.2004.08.003.
   Google Scholar